Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-02-02 Sale | 2026-02-04 5:07 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 243,541 | $42.54 | $10,360,814 | 73,275 (Indirect Direct) | View |
| 2026-01-30 Sale | 2026-02-02 4:59 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $41.09 | $821,810 | 26,418 (Indirect Direct) | View |
| 2026-01-23 Sale | 2026-01-26 4:10 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $40.26 | $805,110 | 46,418 (Indirect Direct) | View |
| 2026-01-20 Sale | 2026-01-23 4:48 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $39.35 | $2,737,940 | 86,400 (Indirect Direct) | View |
| 2026-01-16 Sale | 2026-01-20 5:00 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $39.52 | $790,346 | 66,418 (Indirect Direct) | View |
| 2026-01-09 Sale | 2026-01-13 5:37 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $40.78 | $815,634 | 86,418 (Indirect Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:18 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $38.42 | $2,673,041 | 90,150 (Indirect Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:17 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $38.48 | $769,650 | 106,418 (Indirect Direct) | View |
| 2025-12-26 Sale | 2025-12-29 4:58 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $39.32 | $786,380 | 126,418 (Indirect Direct) | View |
| 2025-12-19 Sale | 2025-12-22 4:09 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $38.38 | $767,582 | 146,418 (Indirect Direct) | View |
| 2025-12-17 Sale | 2025-12-19 5:24 pm | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 110,000 | $38.55 | $4,240,333 | 779,915 (Indirect) | View |
| 2025-12-16 Sale | 2025-12-17 5:43 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $38.32 | $766,420 | 166,418 (Indirect Direct) | View |
| 2025-12-15 Sale | 2025-12-17 5:39 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $38.36 | $2,669,172 | 93,900 (Indirect Direct) | View |
| 2025-12-05 Sale | 2025-12-09 5:00 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 41,576 | $39.15 | $1,627,815 | 186,418 (Indirect Direct) | View |
| 2025-12-03 Sale | 2025-12-05 5:01 pm | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 110,000 | $39.77 | $4,375,008 | 889,915 (Indirect) | View |
| 2025-12-01 Sale | 2025-12-03 5:11 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $39.87 | $2,773,956 | 97,650 (Indirect Direct) | View |
| 2025-12-01 Sale | 2025-12-03 5:10 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 41,575 | $39.92 | $1,659,489 | 227,994 (Indirect Direct) | View |
| 2025-11-24 Sale | 2025-11-26 5:01 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $38.55 | $2,682,505 | 101,400 (Indirect Direct) | View |
| 2025-11-19 Sale | 2025-11-21 4:55 pm | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 135,426 | $38.34 | $5,192,656 | 993,831 (Indirect Direct) | View |
| 2025-11-17 Sale | 2025-11-19 4:53 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,594 | $39.3 | $2,735,329 | 105,150 (Indirect Direct) | View |
| 2025-08-11 Sale | 2025-08-11 4:35 pm | Royalty Pharma plc | RPRX | Norden Gregory Director | 33,500 | $36.23 | $1,213,749 | 194,848 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2026-01-06 4:20 pm | N/A N/A | Royalty Pharma plc | RPRX | McGivern Arthur Richard EVP, Investments & GC | 0 | $0 | 730,834 (Indirect) | View |
| 2025-12-31 Option Award | 2026-01-02 4:06 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 967 | $38.74 | 73,132 (Direct) | View |
| 2025-11-05 Option Award | 2025-11-07 4:19 pm | N/A N/A | Royalty Pharma plc | RPRX | Legorreta Pablo G. CEO, Chairman of the Board | 36,559 | $0 | 4,545,330 (Direct) | View |
| 2025-11-05 Option Award | 2025-11-07 4:18 pm | N/A N/A | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 6,168 | $0 | 898,900 (Indirect) | View |
| 2025-11-05 Option Award | 2025-11-07 4:18 pm | N/A N/A | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 6,168 | $0 | 1,135,341 (Indirect) | View |
| 2025-11-05 Option Award | 2025-11-07 4:18 pm | N/A N/A | Royalty Pharma plc | RPRX | Hite Christopher EVP & Vice Chairman | 6,168 | $0 | 728,510 (Indirect) | View |
| 2025-11-07 Conversion | 2025-11-07 4:16 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 176,000 | $0 | 516,981 (Indirect) | View |
| 2025-11-05 Option Award | 2025-11-07 4:16 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 4,626 | $0 | 516,981 (Direct) | View |
| 2025-09-30 Option Award | 2025-09-30 4:54 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 1,047 | $35.79 | 72,165 (Direct) | View |
| 2025-08-08 Conversion | 2025-08-11 4:35 pm | N/A N/A | Royalty Pharma plc | RPRX | Norden Gregory Director | 159,126 | $0 | 194,848 (Direct) | View |
| 2025-08-08 Gift | 2025-08-08 5:00 pm | N/A N/A | Royalty Pharma plc | RPRX | Legorreta Pablo G. CEO, Chairman of the Board | 60,000 | $0 | 10,888,337 (Direct) | View |
| 2025-08-06 Option Award | 2025-08-08 5:00 pm | N/A N/A | Royalty Pharma plc | RPRX | Legorreta Pablo G. CEO, Chairman of the Board | 21,901 | $0 | 10,888,337 (Direct) | View |
| 2025-08-08 Gift | 2025-08-08 4:58 pm | N/A N/A | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 1,000 | $0 | 1,537,550 (Indirect) | View |
| 2025-08-06 Option Award | 2025-08-08 4:58 pm | N/A N/A | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 3,696 | $0 | 1,537,550 (Indirect) | View |
| 2025-08-08 Gift | 2025-08-08 4:56 pm | N/A N/A | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 8,500 | $0 | 1,881,905 (Direct) | View |
| 2025-08-06 Option Award | 2025-08-08 4:56 pm | N/A N/A | Royalty Pharma plc | RPRX | Lloyd George W. EVP, Investments & CLO | 3,696 | $0 | 1,881,905 (Indirect) | View |
| 2025-08-06 Option Award | 2025-08-08 4:54 pm | N/A N/A | Royalty Pharma plc | RPRX | Hite Christopher EVP & Vice Chairman | 3,696 | $0 | 722,342 (Indirect) | View |
| 2025-08-08 Gift | 2025-08-08 4:52 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 3,000 | $0 | 368,355 (Indirect) | View |
| 2025-08-06 Option Award | 2025-08-08 4:52 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 2,772 | $0 | 368,355 (Direct) | View |
| 2025-07-31 Option Award | 2025-07-31 8:45 pm | N/A N/A | Royalty Pharma plc | RPRX | WEATHERMAN ELIZABETH H Director | 8,558 | $0 | 8,558 (Direct) | View |
| 2025-07-31 Option Award | 2025-07-31 8:42 pm | N/A N/A | Royalty Pharma plc | RPRX | Ho Carole Director | 8,558 | $0 | 8,558 (Direct) | View |
| 2025-06-30 Option Award | 2025-06-30 5:06 pm | N/A N/A | Royalty Pharma plc | RPRX | Fernandez Henry A Director | 1,064 | $35.24 | 123,524 (Direct) | View |
| 2025-06-30 Option Award | 2025-06-30 5:04 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 1,064 | $35.24 | 71,118 (Direct) | View |